Jove
Visualize
联系我们

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The 2026 American Association for Thoracic Surgery Expert Consensus Document: Evaluation and management of N2+ non-small cell lung cancer.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Should minimally invasive surgery be the standard approach for early-stage thymoma? A 20-year experience.

JTCVS techniques·2025
Same author

Lobectomy improves disease-free survival over sublobar resection for high-risk stage IA non-small cell lung cancer.

The Journal of thoracic and cardiovascular surgery·2025
Same author

Nerve Injuries During Thoracic Surgery.

Thoracic surgery clinics·2025
Same author

Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection.

The Annals of thoracic surgery·2024
Same author

Robotic Resection of Spinal and Paraspinal Tumors.

Operative neurosurgery (Hagerstown, Md.)·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 7, 2026

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.4K

瘤的胸膜外科手术:关于最佳方法的观点

Matthew Skovgard1, Bernard Park2

  • 1University of California, San Francisco. San Francisco, CA.

Seminars in thoracic and cardiovascular surgery
|December 28, 2025
PubMed
概括

胸膜上皮瘤 (TETs) 的手术策略正在发展. 最少侵入性的方法在早期阶段提供了好处,而高级阶段需要复杂的切除和多式疗法以获得最佳结果.

科学领域:

  • 胸部外科手术 胸部外科手术
  • 手术瘤学手术瘤学
  • 在瘤学瘤学.

背景情况:

  • 胸膜上皮瘤 (TETs) 存在各种临床挑战.
  • 量身定制的手术策略对于优化患者的治疗结果至关重要.
  • 目前的证据综合是指导手术决策的必要条件.

研究的目的:

  • 审查和综合目前关于胸膜上皮瘤 (TETs) 手术方法的证据.
  • 强调瘤阶段,解剖学和多学科规划在手术策略中的作用.
  • 讨论在TET手术中不断发展的技术和未来的研究方向.

主要方法:

  • 对TETs手术方法的当前证据进行系统审查.
  • 强调瘤阶段,解剖学考虑和多学科规划.
  • 对微创手术与开放手术和多式疗法的结果分析.

主要成果:

  • 最少侵入性技术 (VATS,机器人) 显示了与早期TETs (I/II阶段) 的开放手术相比较的瘤结果,并改善了恢复.
  • 机器人胸膜切除术在减少血液流失和并发症方面具有优势.
  • 局部发达的瘤 (IIIA-B阶段) 和IVA阶段的疾病需要复杂的切除和多模式治疗,个性化管理至关重要.

更多相关视频

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
04:09

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter

Published on: September 20, 2024

768
Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation
08:35

Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation

Published on: December 29, 2014

17.3K

相关实验视频

Last Updated: Jan 7, 2026

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.4K
Minimal Invasive Resection of Large Retrosternal Thyroid Goiter
04:09

Minimal Invasive Resection of Large Retrosternal Thyroid Goiter

Published on: September 20, 2024

768
Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation
08:35

Complete Thymectomy in Adult Rats with Non-invasive Endotracheal Intubation

Published on: December 29, 2014

17.3K

结论:

  • 对TET的手术管理正在推进,整合了最小侵入性技术和多式疗法.
  • R0切除仍然是首要任务,关于淋巴切除术和部分甲状腺切除术的辩论仍在进行中.
  • 对于像TET这样的罕见恶性瘤,大量的中心和国际合作至关重要,需要进一步的前性研究.